ECSP12011787A - Polipéptidos para unión al "receptor para productos finales de glicosilación avanzada" así como composiciones y métodos que implican a los mismos - Google Patents
Polipéptidos para unión al "receptor para productos finales de glicosilación avanzada" así como composiciones y métodos que implican a los mismosInfo
- Publication number
- ECSP12011787A ECSP12011787A ECSP12011787A ECSP12011787A EC SP12011787 A ECSP12011787 A EC SP12011787A EC SP12011787 A ECSP12011787 A EC SP12011787A EC SP12011787 A ECSP12011787 A EC SP12011787A
- Authority
- EC
- Ecuador
- Prior art keywords
- polypeptide
- rpfga
- polipeptides
- glycosilation
- involve
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Cardiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Rheumatology (AREA)
- Wood Science & Technology (AREA)
- Hospice & Palliative Care (AREA)
- Zoology (AREA)
- Dermatology (AREA)
- Physics & Mathematics (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
Abstract
La presente invención se refiere a un polipéptido o complejo polipeptídico que comprende al menos dos secuencias de aminoácidos dispuestas de tal modo que se permita la unión específica del "receptor para productos finales de glicosilación avanzada" (RPFGA), uno o más ácido(s) nucleico(s) que codifica(n) para el polipéptido o complejo polipeptídico, una célula que produce un anticuerpo contra RPFGA, una composición farmacéutica que comprende al menos un polipéptido o ácido nucleico como se ha definido anteriormente, opcionalmente para tratar una enfermedad o trastorno relacionado con RPFGA y un método para diagnosticar una enfermedad o trastorno relacionado con RPFGA.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP09290778A EP2308896A1 (en) | 2009-10-09 | 2009-10-09 | Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same |
EP09290845A EP2319871A1 (en) | 2009-11-05 | 2009-11-05 | Polypeptides for binding to the "receptor for advanced glycation endproducts" as well as compositions and methods involving the same |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP12011787A true ECSP12011787A (es) | 2012-10-30 |
Family
ID=43448431
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSP12011787 ECSP12011787A (es) | 2009-10-09 | 2012-04-05 | Polipéptidos para unión al "receptor para productos finales de glicosilación avanzada" así como composiciones y métodos que implican a los mismos |
Country Status (19)
Country | Link |
---|---|
US (1) | US20120282637A1 (es) |
EP (1) | EP2486058A1 (es) |
JP (1) | JP2013507115A (es) |
KR (1) | KR20120089863A (es) |
CN (1) | CN102686611A (es) |
AU (1) | AU2010305374A1 (es) |
BR (1) | BR112012007821A2 (es) |
CA (1) | CA2777237A1 (es) |
CL (1) | CL2012000886A1 (es) |
CR (1) | CR20120139A (es) |
EC (1) | ECSP12011787A (es) |
IL (1) | IL218968A0 (es) |
MA (1) | MA33661B1 (es) |
MX (1) | MX2012004090A (es) |
PE (1) | PE20121689A1 (es) |
RU (1) | RU2558301C2 (es) |
TN (1) | TN2012000138A1 (es) |
WO (1) | WO2011042548A1 (es) |
ZA (1) | ZA201202099B (es) |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UA112434C2 (uk) | 2011-05-27 | 2016-09-12 | Ґлаксо Ґруп Лімітед | Антигензв'язувальний білок, який специфічно зв'язується з всма |
GB201200563D0 (en) * | 2012-01-13 | 2012-02-29 | Imp Innovations Ltd | Binding molecule |
WO2014167826A1 (ja) * | 2013-04-08 | 2014-10-16 | 株式会社免疫生物研究所 | アミロイド前駆体タンパク質のα-セクレターゼ切断後のC末端側断片の切断面を特異的に認識する抗体及びその利用 |
US11668721B2 (en) | 2013-06-04 | 2023-06-06 | The Trustees Of The University Of Pennsylvania | Methods for diagnosing and treating bicuspid aortic valve and/or aortopathies |
MX371496B (es) | 2013-08-30 | 2020-01-31 | Immunogen Inc | Anticuerpos y ensayos para la detección del receptor 1 de folato. |
EP3633381A3 (en) | 2013-12-05 | 2020-07-29 | The Broad Institute, Inc. | Compositions and methods for identifying and treating cachexia or pre-cachexia |
EP3207062A1 (en) * | 2014-10-16 | 2017-08-23 | The Broad Institute Inc. | Compositions and methods for identifying and treating cachexia or pre-cachexia |
JP6679096B2 (ja) * | 2014-10-21 | 2020-04-15 | 学校法人 久留米大学 | Rageアプタマーおよびその用途 |
WO2016070001A1 (en) * | 2014-10-31 | 2016-05-06 | Jounce Therapeutics, Inc. | Methods of treating conditions with antibodies that bind b7-h4 |
ES2956662T3 (es) * | 2015-05-12 | 2023-12-26 | Syntimmune Inc | Anticuerpos anti-FcRn humanizados con afinidad madurada |
US10787517B2 (en) | 2015-05-18 | 2020-09-29 | Agensys, Inc. | Antibodies that bind to AXL proteins |
JP6857138B2 (ja) | 2015-05-18 | 2021-04-14 | アジェンシス,インコーポレイテッド | Axlタンパク質に結合する抗体 |
US20180355033A1 (en) | 2015-06-10 | 2018-12-13 | Dana-Farber Cancer Institute, Inc. | Antibodies, compounds and screens for identifying and treating cachexia or pre-cachexia |
WO2016201319A1 (en) * | 2015-06-10 | 2016-12-15 | The Broad Institute Inc. | Antibodies, compounds and screens for identifying and treating cachexia or pre-cachexia |
JP6578595B2 (ja) * | 2015-08-28 | 2019-09-25 | 国立研究開発法人科学技術振興機構 | 抗アセチル化ヒストンh4抗体 |
SG11201800127WA (en) * | 2015-09-08 | 2018-03-28 | Eisai R&D Man Co Ltd | Anti-epha4 antibody |
CA2994888A1 (en) | 2015-09-17 | 2017-03-23 | Immunogen, Inc. | Therapeutic combinations comprising anti-folr1 immunoconjugates |
US11111296B2 (en) | 2015-12-14 | 2021-09-07 | The Broad Institute, Inc. | Compositions and methods for treating cardiac dysfunction |
CN108570106B (zh) * | 2017-03-10 | 2021-07-16 | 北京天广实生物技术股份有限公司 | 抗埃博拉病毒单克隆抗体、其制备方法及用途 |
BR112020001679A2 (pt) | 2017-08-02 | 2020-07-21 | Phanes Therapeutics, Inc. | anticorpos anti-cd47 e usos dos mesmos |
EP3773718A4 (en) | 2018-04-06 | 2022-01-19 | aTyr Pharma, Inc. | COMPOSITIONS AND METHODS WITH ANTI-NRP2 ANTIBODIES |
US11345744B2 (en) | 2019-05-07 | 2022-05-31 | William R Church | Antibody specific to Staphylococcus aureus, therapeutic method and detection method using same |
JP2022539178A (ja) * | 2019-06-26 | 2022-09-07 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッド | Il1rap結合タンパク質 |
AU2020358854A1 (en) | 2019-10-03 | 2022-05-26 | Atyr Pharma, Inc. | Compositions and methods comprising anti-NRP2 antibodies |
WO2022019924A1 (en) * | 2020-07-23 | 2022-01-27 | Church William R | Antibody specific to staphylococcus aureus, therapeutic method and detection method using same |
CN113956363B (zh) * | 2021-10-13 | 2023-03-31 | 宜明昂科生物医药技术(上海)股份有限公司 | 靶向cd47和cd24的重组融合蛋白及其制备和用途 |
CN116554311B (zh) * | 2023-05-04 | 2023-11-21 | 中国人民解放军军事科学院军事医学研究院 | 抗CD2v-N的特异性抗体及其应用 |
Family Cites Families (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
DK0772619T4 (da) | 1994-07-15 | 2011-02-21 | Univ Iowa Res Found | Immunmodulatoriske oligonukleotider |
US5864018A (en) * | 1996-04-16 | 1999-01-26 | Schering Aktiengesellschaft | Antibodies to advanced glycosylation end-product receptor polypeptides and uses therefor |
MY131805A (en) * | 1997-09-18 | 2007-09-28 | Biogen Idec Inc | Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis. |
AT409085B (de) | 2000-01-28 | 2002-05-27 | Cistem Biotechnologies Gmbh | Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen |
TR200302015T4 (tr) | 2000-06-08 | 2004-01-21 | Intercell Biomedizinische Forschungs-Und Entwicklungs Ag | İmüno-uyarıcı oligodeoksinükleotitler |
AT410173B (de) | 2000-06-08 | 2003-02-25 | Cistem Biotechnologies Gmbh | Antigene zusammensetzung |
EP1309345A2 (en) | 2000-08-17 | 2003-05-14 | Cistem Biotechnologies GmbH | Cathelicidins as vaccine adjuvants |
AT410635B (de) | 2000-10-18 | 2003-06-25 | Cistem Biotechnologies Gmbh | Vakzin-zusammensetzung |
ATE366308T1 (de) | 2001-05-21 | 2007-07-15 | Intercell Ag | Immunostimulierende oligodeoxyribonuklein moleküle |
US7425328B2 (en) * | 2003-04-22 | 2008-09-16 | Purdue Pharma L.P. | Tissue factor antibodies and uses thereof |
US20080008719A1 (en) * | 2004-07-10 | 2008-01-10 | Bowdish Katherine S | Methods and compositions for the treatment of prostate cancer |
KR20090003308A (ko) * | 2006-03-02 | 2009-01-09 | 온코세라피 사이언스 가부시키가이샤 | Reg4 단백질을 이용한 췌장암 진단 방법 |
CN101448857A (zh) * | 2006-03-21 | 2009-06-03 | 惠氏公司 | 预防和治疗淀粉样蛋白生成疾病的方法 |
RU2008134135A (ru) * | 2006-03-21 | 2010-04-27 | Вайет (Us) | Соединения-антагонисты белка rage и способы их применения |
EP2035456A1 (en) * | 2006-06-22 | 2009-03-18 | Novo Nordisk A/S | Production of bispecific antibodies |
CN100586960C (zh) * | 2006-06-23 | 2010-02-03 | 陈志南 | HAb18GC2单抗和其轻、重链可变区基因及应用 |
WO2008137552A2 (en) * | 2007-05-02 | 2008-11-13 | Medimmune, Llc | Anti-rage antibodies and methods of use thereof |
BRPI0911758A8 (pt) * | 2008-05-09 | 2017-10-10 | Abbott Lab | Anticorpos para receptor de produtos finais de glicação avançada (rage) e utilizações dos mesmos |
-
2010
- 2010-10-08 MX MX2012004090A patent/MX2012004090A/es not_active Application Discontinuation
- 2010-10-08 CN CN201080045826XA patent/CN102686611A/zh active Pending
- 2010-10-08 CA CA2777237A patent/CA2777237A1/en not_active Abandoned
- 2010-10-08 AU AU2010305374A patent/AU2010305374A1/en not_active Abandoned
- 2010-10-08 RU RU2012118598/10A patent/RU2558301C2/ru not_active IP Right Cessation
- 2010-10-08 PE PE2012000444A patent/PE20121689A1/es not_active Application Discontinuation
- 2010-10-08 BR BR112012007821A patent/BR112012007821A2/pt not_active IP Right Cessation
- 2010-10-08 KR KR1020127011908A patent/KR20120089863A/ko not_active Application Discontinuation
- 2010-10-08 US US13/500,400 patent/US20120282637A1/en not_active Abandoned
- 2010-10-08 EP EP10771381A patent/EP2486058A1/en not_active Withdrawn
- 2010-10-08 WO PCT/EP2010/065124 patent/WO2011042548A1/en active Application Filing
- 2010-10-08 JP JP2012532622A patent/JP2013507115A/ja active Pending
-
2012
- 2012-03-22 ZA ZA2012/02099A patent/ZA201202099B/en unknown
- 2012-03-22 CR CR20120139A patent/CR20120139A/es unknown
- 2012-03-27 TN TNP2012000138A patent/TN2012000138A1/en unknown
- 2012-04-01 IL IL218968A patent/IL218968A0/en unknown
- 2012-04-04 MA MA34756A patent/MA33661B1/fr unknown
- 2012-04-05 EC ECSP12011787 patent/ECSP12011787A/es unknown
- 2012-04-05 CL CL2012000886A patent/CL2012000886A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
PE20121689A1 (es) | 2012-12-14 |
JP2013507115A (ja) | 2013-03-04 |
MX2012004090A (es) | 2012-04-20 |
CL2012000886A1 (es) | 2012-12-14 |
KR20120089863A (ko) | 2012-08-14 |
TN2012000138A1 (en) | 2013-09-19 |
US20120282637A1 (en) | 2012-11-08 |
EP2486058A1 (en) | 2012-08-15 |
MA33661B1 (fr) | 2012-10-01 |
CN102686611A (zh) | 2012-09-19 |
ZA201202099B (en) | 2012-11-28 |
BR112012007821A2 (pt) | 2017-05-30 |
CA2777237A1 (en) | 2011-04-14 |
AU2010305374A1 (en) | 2012-05-03 |
WO2011042548A1 (en) | 2011-04-14 |
IL218968A0 (en) | 2012-07-31 |
RU2012118598A (ru) | 2013-11-20 |
CR20120139A (es) | 2012-07-13 |
RU2558301C2 (ru) | 2015-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP12011787A (es) | Polipéptidos para unión al "receptor para productos finales de glicosilación avanzada" así como composiciones y métodos que implican a los mismos | |
BR112014012789A2 (pt) | agentes terapêuticos compreendendo sequências de aminoácidos de insulina | |
BR112012015740A2 (pt) | anticorpos de anti-flt3 e metodos de uso dos mesmos | |
TW201129381A (en) | Antibodies against human CSF-1R and uses thereof | |
MY183588A (en) | New salvianolic acid compound l, preparation method and use thereof | |
MX356337B (es) | Anticuerpos contra csf-1r humano y sus usos. | |
BR112015012933A2 (pt) | proteínas de ligação ao antígeno bcma | |
NZ704662A (en) | Crystalline forms of the prolyl hydroxylase inhibitor [(4-hydroxy-1-methyl-7-phenoxy-isoquinoline-3-carbonyl)-amino]-acetic acid | |
AR090465A1 (es) | Formas solidas de un profarmaco de nucleotidos de tiofosforamidato | |
MY178926A (en) | Bispecific anti-vegf/anti-ang-2 antibodies | |
EA201501122A8 (ru) | Новые агонисты соматостатиновых рецепторов подтипа 4 (sstr4) | |
MY195289A (en) | Anti IL-36R Antibodies | |
AU2010233994A8 (en) | Bispecific anti-ErbB-3/anti-c-Met antibodies | |
BR112013032434A2 (pt) | restauração dentária, método para sua produção e vidro cerâmico | |
EA200970247A1 (ru) | Способ получения оптического активного n-защищенного 3-аминопирролидина или оптически активного n-защищенного 3-аминопиперидина и соответствующих кетонов путем оптического разделения рацемических смесей аминов с использованием бактериальной омега-трансаминазы | |
BRPI0908421B8 (pt) | solução estável de um composto farmacêutico | |
MX2012002458A (es) | Anticuerpos anti-cdcp1 humanizados. | |
IN2012MN02923A (es) | ||
AR081696A1 (es) | Anticuerpo para el diagnostico y/o pronostico de cancer | |
MY161268A (en) | PEPTIDE OR PEPTIDE COMPLEX BINDING TO α2 INTEGRIN AND METHODS AND USES INVOLVING THE SAME | |
MX359854B (es) | Anticuerpos anti-cxcr3. | |
NZ703597A (en) | Mutant fragments of ospa and methods and uses relating thereto | |
EA201490395A1 (ru) | Способ получения фармацевтических композиций, содержащих финголимод | |
CY1121238T1 (el) | Παραγωγα παντοθενικου για την αντιμετωπιση νευρολογικων διαταραχων | |
WO2013087929A3 (de) | Verfahren zur identifizierung von markersequenzen für gynäkologisches malignom |